{"product_id":"generic-olaparib-oladx-150","title":"OLADX 150 (Olaparib)","description":"\u003ch2\u003e\u003cspan id=\"About_Olaparib\"\u003eAbout Olaparib\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eOlaparib is a poly (ADP ribose) polymerase (PARP) inhibitor, at least before monotherapy Germline BRCA gene mutations associated with harmful or suspected harmful after 3 chemotherapy (FDA also approved the gene Detection reagent) for patients with advanced ovarian cancer.\u003c\/p\u003e\u003cp\u003eOlaparib was approved by the FDA due to its objective response rate and response duration. Further of this indication\u003c\/p\u003e\u003cp\u003eApproval depends on the results of clinical benefit in confirmatory clinical trials.\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Dose_and_administration_method\"\u003eDose and administration method\u003c\/span\u003e\u003c\/h2\u003e\u003col\u003e\u003cli\u003eMethod of administration\u003c\/li\u003e\u003c\/ol\u003e\u003cul\u003e\n\u003cli\u003eThe recommended dose is 400 mg twice a day, orally, either before or after meals.\u003c\/li\u003e\n\u003cli\u003eContinue to use until the disease progresses or unacceptable toxicity occurs.\u003c\/li\u003e\n\u003cli\u003eIf adverse reactions occur, consider discontinuing the medication or reducing the dose.\u003c\/li\u003e\n\u003cli\u003eFor patients with mild renal impairment (creatinine clearance (CLcr)=31-50mL\/min), the dose is reduced 300mg\/time.\u003c\/li\u003e\n\u003c\/ul\u003e\u003col start=\"2\"\u003e\u003cli\u003eDosage specifications\u003c\/li\u003e\u003c\/ol\u003e\u003cul\u003e\u003cli\u003eCapsule, 50mg.\u003c\/li\u003e\u003c\/ul\u003e\u003col start=\"3\"\u003e\u003cli\u003eContraindications: None.\u003c\/li\u003e\u003c\/ol\u003e\u003ch2\u003e\u003cspan id=\"Warnings_and_Precautions\"\u003eWarnings and Precautions\u003c\/span\u003e\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eMyelodysplastic syndrome\/acute myelogenous leukemia (MDS\/AML): The patient is taking European MDS\/AML appeared after Lini, and a large number of reports were fatal. Baseline monitoring of whole blood cells every month after treatment Cell count. Once diagnosed with MDS\/AML, Orini was stopped immediately.\u003c\/li\u003e\n\u003cli\u003ePneumonia: The patient develops pneumonia after taking Olini. In some cases, it is fatal. Once the lungs appear The treatment was discontinued for inflammatory symptoms, and Olini was discontinued after diagnosis.\u003c\/li\u003e\n\u003cli\u003eFetal-embryotoxicity: Olini can be fatal to the fetus. Advise women with reproductive capacity to suffer Patients take effective contraceptive measures during treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003e\u003cspan id=\"Adverse_reactions\"\u003eAdverse reactions\u003c\/span\u003e\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eCommon adverse reactions (≥20%) in clinical trials include anemia, nausea, fatigue (including weakness), Vomiting, diarrhea, dizziness, indigestion, headache, loss of appetite, nasopharyngitis\/pharyngitis\/URI, cough, close Joint pain\/muscle pain, back pain, dermatitis\/rash, abdominal pain\/discomfort.\u003c\/li\u003e\n\u003cli\u003eCommon laboratory abnormalities (≥25%) include: creatinine, increase in average red blood cell volume; blood Globin, lymphocytes, absolute neutrophils, thrombocytopenia.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003e\u003cspan id=\"Storage_method\"\u003eStorage method\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eStore between 20-25°C.\u003c\/p\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797953277995,"sku":"RL3020241020345","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-153-jpg.webp?v=1787022196","url":"https:\/\/xomeds.com\/products\/generic-olaparib-oladx-150","provider":"XOMEDS","version":"1.0","type":"link"}